Favorite  |  Set Home
Products > JAK/STAT > EGFR > CNX-2006
Product name : CNX-2006
Item : CR1778
Price : 200mg, $750;500mg, $1290; 1g, $1990; 2g, $2995
contact : Send inquiry to: info@acesobio.com
CAS : 1375465-09-0
Molecular Weight : 545.53
Formula : C₂₆H₂₇F₄N₇O₂
Storage : at -20°C
Additional information : We offer significant discount for bulky quantity order,Please ask price and availability of other quantities
 Enlarge Image                   Back
             [Next Product]→

 Chemical Information
M.Wt 545.53 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C26H27F4N7O2
CAS No 1375465-09-0

DMSO 100mg/ml; Water <1 mg/ml

Biological Activity of CNX-2006


CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
IC50 value: <20 nM
Target: Mutant EGFR
CNX-2006 is a novel irreversible EGFR tyrosine kinase inhibitor, specifically inhibits activating mutations of EGFR as well as the T790M mutation while having very weak inhibition at wild-type EGFR. In in vitro modeling of acquired resistance, continuous CNX-2006 treatment on drug-sensitive EGFR mutant cells leads to resistance more slowly than erlotinib. Dose escalation with CNX-2006 leads to differential effects in different lines, but does not select for T790M-mediated resistance. CNX-2006 resistent cells shows increased expression of EMT markers and MMP9. CNX-2006 is effective in H1975 (EGFR L858R/T790M) xenograft model.


[1]. Kadoaki Ohashi, et al. CNX-2006, a Novel Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor, Selectively Inhibits EGFR T790M and Fails to Induce T790M-Mediated Resistance In Vitro

[2]. Elena Galvani, et al. Role of epithelial-mesenchymal transition (EMT) in sensitivity to CNX- 2006,a novel mutant-selective EGFR inhibitor which overcomes in vitro T790M-mediated resistance in NSCLC

Related Products :
Price: 200mg, $750;500mg, $1290; 1g, $1990; 2g, $2995